Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

被引：0
|
作者：
Mei Dong
Zhi-Qiang Ning
Pu-Yuan Xing
Jia-Lian Xu
Hai-Xiang Cao
Gui-Fang Dou
Zhi-Yun Meng
Yuan-Kai Shi
Xian-Ping Lu
Feng-Yi Feng
机构：
[1] Chinese Academy of Medical Sciences,Department of Medical Oncology, Cancer Institute and Hospital
[2] Chipscreen Biosciences Ltd.,Laboratory of Drug Metabolism and Pharmacokinetics
[3] Tigermed Consulting Ltd.,undefined
[4] Institute of Transfusion Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Chidamide; HDAC inhibitor; Phase I; Solid tumor; Lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1413 / 1422
页数：9
相关论文
共 50 条
  • [21] A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
    Klaus Mross
    Heike Richly
    Annette Frost
    Dirk Scharr
    Bahar Nokay
    Ralph Graeser
    Chooi Lee
    James Hilbert
    Rainer-George Goeldner
    Oliver Fietz
    Max E. Scheulen
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 405 - 417
  • [22] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elez, Elena
    Gomez-Roca, Carlos
    Soto Matos-Pita, Arturo
    Argiles, Guillem
    Valentin, Thibaud
    Coronado, Cinthya
    Iglesias, Jorge
    Macarulla, Teresa
    Betrian, Sarah
    Fudio, Salvador
    Zaragoza, Katrin
    Tabernero, Josep
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
  • [23] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
    Zhu, Mojun
    Molina, Julian R.
    Dy, Grace K.
    Croghan, Gary A.
    Qi, Yingwei
    Glockner, James
    Hanson, Lorelei J.
    Roos, Michelle M.
    Tan, Angelina D.
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1755 - 1762
  • [24] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
    Mojun Zhu
    Julian R. Molina
    Grace K. Dy
    Gary A. Croghan
    Yingwei Qi
    James Glockner
    Lorelei J. Hanson
    Michelle M. Roos
    Angelina D. Tan
    Alex A. Adjei
    Investigational New Drugs, 2020, 38 : 1755 - 1762
  • [25] A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
    Collier, Katharine A.
    Valencia, Hugo
    Newton, Herbert
    Hade, Erinn M.
    Sborov, Douglas W.
    Cavaliere, Robert
    Poi, Ming
    Phelps, Mitch A.
    Liva, Sophia G.
    Coss, Christopher C.
    Wang, Jiang
    Khountham, Soun
    Monk, Paul
    Shapiro, Charles L.
    Piekarz, Richard
    Hofmeister, Craig C.
    Welling, D. Bradley
    Mortazavi, Amir
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (05) : 599 - 611
  • [26] A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
    Katharine A. Collier
    Hugo Valencia
    Herbert Newton
    Erinn M. Hade
    Douglas W. Sborov
    Robert Cavaliere
    Ming Poi
    Mitch A. Phelps
    Sophia G. Liva
    Christopher C. Coss
    Jiang Wang
    Soun Khountham
    Paul Monk
    Charles L. Shapiro
    Richard Piekarz
    Craig C. Hofmeister
    D. Bradley Welling
    Amir Mortazavi
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 599 - 611
  • [27] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elena Elez
    Carlos Gomez-Roca
    Arturo Soto Matos-Pita
    Guillem Argiles
    Thibaud Valentin
    Cinthya Coronado
    Jorge Iglesias
    Teresa Macarulla
    Sarah Betrian
    Salvador Fudio
    Katrin Zaragoza
    Josep Tabernero
    Jean-Pierre Delord
    Investigational New Drugs, 2019, 37 : 674 - 683
  • [28] Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
    Xu, Jian Ming
    Wang, Yan
    Chen, Yu Ling
    Jia, Ru
    Li, Jie
    Gong, Ji Fang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    Tan, Cui Rong
    Wang, Jian
    Li, Ke
    Sai, Yang
    Zhou, Feng
    Ren, Yong Xin
    Qing, Wei Guo
    Jia, Hong
    Su, Wei Guo
    Shen, Lin
    ONCOTARGET, 2017, 8 (26) : 42076 - 42086
  • [29] A phase I study of bortezomib and temozolomide in patients with advanced solid tumors
    J. Portnow
    P. Frankel
    S. Koehler
    P. Twardowski
    S. Shibata
    C. Martel
    R. Morgan
    M. Cristea
    W. Chow
    D. Lim
    V. Chung
    K. Reckamp
    L. Leong
    T. W. Synold
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 505 - 514
  • [30] A phase i study of ixazomib and erlotinib in patients with advanced solid tumors
    Kato, Shumei
    Adashek, Jacob J.
    Subbiah, Vivek
    Fu, Siqing
    Sun, Mianen
    Nguyen, Ly
    Brown, Elsa J.
    Yap, Timothy A.
    Karp, Daniel D.
    Piha-Paul, Sarina A.
    Hong, David S.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 99 - 105
12345